We are live on
!
Find out more
SCM
Sarissa Capital Management Portfolio holdings
AUM
$158M
1-Year Est. Return
103.7%
This Fund
S&P 500
This Quarter
Est. Return
+0.93%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$402M
AUM Growth
-$190M
(-32%)
Cap. Flow
-$159M
Cap. Flow
% of AUM
-39.49%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
–
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lantheus
LNTH
|
+$2.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$129M |
| 2 |
Gilead Sciences
GILD
|
+$25.9M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$6.76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Innoviva
INVA
$1.55B
| $141M | 34.93% |
7,277,000
| – | – |
|
2
Ironwood Pharmaceuticals
IRWD
$696M
| $67.5M | 16.78% |
16,390,000
| – | – |
|
|
3
Gilead Sciences
GILD
$162B
| $64M | 15.91% |
763,333
-339,949
| -31% | -$25.9M |
|
4
Cytokinetics
CYTK
$10.5B
| $58.6M | 14.57% |
1,110,000
| – | – |
|
5
Neurocrine Biosciences
NBIX
$16.8B
| $47.3M | 11.76% |
410,483
| – | – |
|
|
AMRN
6
Amarin Corp
AMRN
$298M
| $15.6M | 3.87% |
1,242,531
| – | – |
|
|
7
Biogen
BIIB
$30B
| $5.22M | 1.3% |
26,950
-616,050
| -96% | -$129M |
|
|
8
Lantheus
LNTH
$6.49B
| $2.85M | 0.71% |
+26,000
| New | +$2.7M |
|
9
Vor Biopharma
VOR
$1.15B
| $433K | 0.11% |
30,900
| – | – |
|
|
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
| $291K | 0.07% |
185,183
| – | – |
|
|
11
BioCryst Pharmaceuticals
BCRX
$2.28B
| – | – |
-1,094,168
| Closed | -$6.76M |
|
Similar funds
4A
DAM
PCP
CF
HEM
SF
AC
EP
Sarissa Capital Management's Q3 2024 Portfolio in Review
As of Q3 2024, Sarissa Capital Management held 11 positions worth $402M, down 32% from $592M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Sarissa Capital Management withdrew a net $159M in Q3 2024, closing 1 position and reducing 2 holdings. Its most notable exit was BioCryst Pharmaceuticals, an estimated $6.76M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Sarissa Capital Management opened a new position in Lantheus worth $2.85M.
- Sarissa Capital Management's largest Q3 2024 buy was Lantheus: 26,000 shares worth $2.85M.
- Sarissa Capital Management's biggest Q3 2024 reduction was Biogen, cutting an estimated $129M.
- Sarissa Capital Management fully exited BioCryst Pharmaceuticals in Q3 2024, selling an estimated $6.76M.
- Sarissa Capital Management's ten largest holdings make up 100% of its $402M portfolio in Q3 2024.
- Sarissa Capital Management opened 1 new position and closed 1 in Q3 2024.
- Sarissa Capital Management's portfolio value fell 32% quarter-over-quarter to $402M.
Based on Sarissa Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.